

Available online at www.sciencedirect.com

ScienceDirect

journal homepage: www.elsevier.com/locate/jval

ABSTRACTS

RESEARCH PODIUM PRESENTATIONS – SESSION I

CARDIOVASCULAR DISEASE RESEARCH STUDIES

CV1

LIFETIME HEALTH CARE COSTS OF OBESITY-RELATED COMORBIDITIES IN THE UNITED STATES, 2007–2010

Chang S, Leung MY, Carlsson NP, Colditz GA

Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, St. Louis, MO, USA

OBJECTIVES: This study analyzed lifetime healthcare costs of obesity-related comorbidities, including diabetes, hypertension, coronary heart disease (CHD), and stroke. **METHODS:** We used data from the National Health Interview Survey (NHIS), 2007–2010, and linked it to the Medical Expenditure Panel Survey to estimate annual healthcare expenditures. We excluded pregnant women, cancer survivors, and underweight individuals. Disease risks were estimated using the National Health and Nutrition Examination Survey data. Mortality risks were estimated using the NHIS Linked Mortality Public-Use Files and predicted for the 2007–2010 population. Analyses were stratified by gender and controlled for age, race, body mass index (BMI) category, comorbidities, smoking, and insurance. Complex sampling designs were adjusted for. A Markov model, populated by disease and mortality estimates and healthcare expenditures, was built to simulate lifetime healthcare expenditures for gender-race-age-BMI group subpopulations. **RESULTS:** We included 18,763 women and 14,793 men. We use insured, non-smoking individuals age 40 as an example. Without obesity-related comorbidities, remaining lifetime healthcare costs ranged from \$90,125 (normal-weight, non-white, non-black men) to \$149,761 (obese white women). With diabetes, costs ranged from \$124,757 (overweight, non-white, non-black men) to \$207,643 (obese white women); with hypertension, costs ranged from \$118,084 (overweight, non-white, non-black men) to \$197,343 (obese white women); with CHD, costs ranged from \$141,753 (normal-weight, non-white, non-black men) to \$225,575 (obese black men); with stroke, costs ranged from \$107,803 (normal-weight, non-white, non-black men) to \$184,283 (obese white women). With two comorbidities, obese black men with hypertension and CHD had the highest costs (\$274,104). With three comorbidities, obese white women with diabetes, hypertension, and CHD incurred the highest costs (\$357,486). With all four comorbidities, obese white women had the highest costs (\$432,102). **CONCLUSIONS:** This study suggests that obesity-related comorbidities impose a significant economic burden. Some subpopulations, e.g., obese white women and obese black men, incur higher healthcare costs than others.

CV2

THE ASSOCIATION BETWEEN ADHERENCE TO CARDIOVASCULAR MEDICATIONS AND HEALTH CARE UTILIZATION

Simon-Tuval T¹, Triki N², Chodick G³, Greenberg D¹¹Ben-Gurion University of the Negev, Beer-Sheva, Israel, ²Maccabi Healthcare Services, Tel-Aviv, Israel, ³Maccabi Healthcare Services and Tel-Aviv University, Tel-Aviv, Israel

OBJECTIVES: Poor adherence to medications for cardiovascular disease (CVD) is associated with adverse health outcomes, but little is known on its impact on healthcare utilization (HCU). We examined whether adherence is related to a long-term decrease in HCU. **METHODS:** A retrospective cohort study of 2220 patients with CVD enrolled in Maccabi Healthcare Services in Israel initiating CVD medication therapy between 2006 and 2008. Adherence was assessed by the proportion of days covered (PDC) with medications. Patients were defined as: non-adherent (PDC<0.4), partially adherent (0.4≤PDC<0.8), and adherent (PDC≥0.8). HCU was estimated following treatment initiation and up to four years. Multivariable GEE models were used to analyze predictors of HCU. Model I included total adherence during the entire follow-up period as well as the interaction between this measure and the follow-up year. Model II included previous and current year's adherence as well as previous year's HCU cost. Both models were adjusted to potential confounders including: age, gender, socioeconomic status, ownership of voluntary supplementary health insurance, and comorbidities. **RESULTS:** The median age of patients was 63 (67% males). Fifty one percent of patients (n=1139) were defined as adherent, 24% as partially adherent and 25% as non-adherent. Model I: The annual HCU costs of adherent patients decreased in 9% following treatment initiation (RR=0.91, 95% confidence interval (CI): 0.88–0.95, P<0.001). This decrease stem predominantly from reduction in hospitalization and medication costs. No significant changes in annual costs following treatment initiation were observed among partially adherent (RR=0.97, 95% CI: 0.88–1.07, P=0.526) and non-adherent (RR=0.99, 95% CI: 0.90–1.09, P=0.785) patients. Model II: No temporal association was found between adherence

and HCU. **CONCLUSIONS:** Adherence to CVD medications is suboptimal. Adherence is associated with long-term decrease in healthcare expenditure. Exploring reasons for the high non-adherence and ways to improve adherence may optimize utilization of health systems' scarce resources.

CV3

PREVALENCE AND DIRECT MEDICAL COSTS ASSOCIATED WITH ANGINA AND CHEST PAIN FOLLOWING PERCUTANEOUS CORONARY INTERVENTION IN THE UNITED STATES

Machacz S¹, Bonafede ², Wade S³, Stephens L¹, Hernandez J¹¹Abbott Vascular, Santa Clara, CA, USA, ²Truven Health Analytics, Cambridge, MA, USA, ³Wade Outcomes Research and Consulting, Salt Lake City, UT, USA

OBJECTIVES: Percutaneous coronary intervention (PCI) is effective in reducing angina and improving quality of life. However, as reported in clinical trials, angina and chest pain remain a clinical challenge post-PCI. Currently there is limited contemporary data on the real world rate and its economic burden. We sought to describe the incidence and direct costs associated with angina or chest pain following a PCI. **METHODS:** Patients undergoing PCI (index event) were identified in the Truven Health MarketScan Commercial and Medicare Supplemental Databases from 2008–2011. Patients were required to have 12 months of continuous enrollment pre- and post-index. Post-index angina and chest pain were defined as an inpatient claim with a principal diagnosis of angina or chest pain, an outpatient claim with an angina or chest pain diagnosis with an accompanying stress test, repeat PCI or cardiac catheterization, more than one month post-index. Total and cardiovascular-specific costs were described 1–3 years post-index in 2013 US\$. Patients with post-index acute coronary syndrome (ACS) were excluded from the cost analysis. **RESULTS:** 51,756 patients met the selection criteria (mean age: 61.8 years, 72% male). The incidence of post-PCI angina or chest pain was 27.8% by one year increasing to 40.1% by three years post-PCI. Average total costs for angina/chest pain patients were 1.8 times higher (+\$14,514) than those without angina, chest pain or ACS (p<0.001) with differences persisting at three years (p<0.001). Post-PCI cardiovascular-related costs were likewise higher for angina/chest pain patients one year (\$18,548 (SD=\$30,525) versus \$7,896 (SD=\$17,638), p<0.001) and three years post-index (\$33,238 (SD=\$43,261) versus \$19,773 (SD=\$34,097), p<0.001). **CONCLUSIONS:** Post-PCI angina and chest pain are common and carry substantial direct medical burden. Strategies to reduce these events could impact the costs and improve outcomes of ischemic heart disease.

CV4

OUTCOMES AND HEALTH RESOURCE UTILIZATION AMONG PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION (HFREF) AT AN ACADEMIC MEDICAL CENTER (AMC) IN THE UNITED STATES

Bress A¹, King J¹, Singhal M¹, Brixner D¹, Kielhorn A², Patel H², Maya J², Biskupiak JE¹, Munger M¹¹University of Utah, Salt Lake City, UT, USA, ²Amgen, Thousand Oaks, CA, USA

OBJECTIVES: To assess clinical characteristics, hospitalizations, and hospitalization charges among a contemporary, real world cohort of HFREF patients. **METHODS:** A retrospective cohort study of HFREF, identified by ICD-9 code 428.x with a left ventricular ejection fraction (LVEF) ≤ 40% between 01/01/08 to 12/31/13 (study period) were identified using an AMC enterprise data warehouse (EDW) that includes electronic health records and billing/administrative claims. Demographic, clinical, and hospitalization/charge data were extracted. The index date was defined as the first mention of an ICD-9 of 428.x within the study period. A subset of prevalent HFREF underwent chart review to obtain detailed medication and medical histories. **RESULTS:** The cohort comprised 1931 HFREF with a mean age of 63±15 years, prevalently Caucasian (70%) males (70%). The average LVEF was 28±9%. Medication data and etiology was assessed in prevalent HFREF (n=989). The prevalent HFREF cohort was predominantly ischemic etiology (67%) and ACEi/ARB/aldosterone antagonists were prescribed in 53%/16%/29%, respectively. Eighty percent were on β-adrenergic blockers. Atrial fibrillation and renal insufficiency were present in 45% and 42%, respectively. Devices were present in 34% (Implantable Cardioverter-Defibrillator) and 16% (Cardiac Resynchronization Therapy) of patients. In the full sample, during a mean follow up period of 34±26 months, all-cause mortality was 18% (13% CV death) at one-year and 23% (16% CV death) at two-years. There were 2106 all-cause hospitalizations of which 972 (46%) were for heart failure (HF). The median length of stay for HF hospitalizations was 4.3 days and the median charge was \$27,230. Among the HF hospitalizations 30-day readmission rates were 167 (21%) for all-cause, and 111 (13%) for HF. **CONCLUSIONS:** In an AMC-based EDW, HFREF was well treated, resulting in a 1-year mortality and 30-day re-admission rates similar to published data. The median charge for a HF hospital stay was \$27,230.

RESEARCH ON DATABASE METHODS STUDIES

DB1

CRITICAL PROBLEMS OF CODING DATA IN HEALTH CARE: OBESITY, SMOKING, AND ALCOHOL USE BY METHOD OF MEASUREMENT

Al Kazzi ES¹, Lau B¹, Li T², Schneider EB¹, Makary MA¹, Hutfless S¹¹Johns Hopkins University School of Medicine, Baltimore, MD, USA, ²Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

OBJECTIVES: The measurement of healthcare is increasingly based on risk-adjusted outcomes derived from coded comorbidities in large datasets. However inaccurate or haphazard assessment of risk factors for morbidity and mortality in medical record codes can have tremendous implications for quality improvement and healthcare reform. The purpose of this study is to compare the prevalence of obesity, overweight, tobacco use and alcohol abuse of a large administrative dataset with a direct data collection survey. **METHODS:** We used the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes for four leading comorbidities in the Nationwide Inpatient Sample (NIS) to compare them with a direct survey in the Behavioral Risk Factor Surveillance System (BRFSS) in 2011. The national and state estimates and the Pearson correlation coefficient for obesity, overweight, smoking and alcohol abuse between NIS and direct survey were calculated. **RESULTS:** Compared with direct participant questioning in BRFSS, NIS reported substantially lower prevalence of obesity, overweight, smoking and alcohol. The prevalence of obesity, overweight, smoking and alcohol were 27.7%, 35.8%, 20.1% and 18.3% in direct survey and 9.6%, 0.21%, 12.2% and 4.6% in NIS. The correlation between NIS and direct survey was 0.27 for obesity ($p=0.06$), 0.09 for overweight ($p=0.55$), 0.62 for smoking ($p<0.01$) and 0.40 for alcohol ($p<0.01$). **CONCLUSIONS:** The prevalence of obesity, tobacco smoking and alcohol abuse based on ICD-9-CM codes in NIS is not consistent with prevalence rates by direct questioning. Patient-level data extraction as a part of Meaningful Use standards, rather than ICD-9-CM codes, would improve the accuracy of these important contributors to patient outcomes in NIS. Ensuring accuracy of important comorbidities is critical to quality improvement efforts and healthcare reform policies that are based on measuring risk-adjusted outcomes.

DB2

A NEW METHOD FOR COUNTING HEMOPHILIA-RELATED BLEEDING EVENTS IN CLAIMS DATA

Shrestha A¹, Eldar-Lissai A², Wu Y¹, Batt K³, Krishnan S², Lakdawalla D⁴¹Precision Health Economics, Los Angeles, CA, USA, ²Biogen Idec, Cambridge, MA, USA, ³Wake Forest School of Medicine, Winston-Salem, NC, USA, ⁴University of Southern California, Los Angeles, CA, USA

OBJECTIVES: Hemophilia-related bleeding events are difficult to quantify. Insurance claims' data may capture the information, but there is no robust methodology to identify these events. **METHODS:** Using 2004-2012 Truven Health MarketScan commercial claims database (coverage of >30 million employees in the United States), we evaluated males under age 65 having ≥ 1 inpatient/ ≥ 2 outpatient claims 30-day apart for hemophilia A or B (ICD-9: 286.0, 286.1), and ≥ 1 pharmacy claim for clotting factors VIII or IX with ≥ 12 months continuous enrollment from first hemophilia treatment were selected. Bleeding events were identified using ICD-9 codes for hemarthrosis, hematoma or other acute bleeds in inpatient/outpatient claims. Hemophilia treatment guidelines recommend 1-14 day treatment depending on bleeding severity. We explored aggregating claims within varying time windows (1, 7, 10, and 14 days) to capture a single bleeding event and assessed sensitivity of the time differences using pairwise rank correlations. **RESULTS:** We identified 2,425 and 269 hemophilia A and B patients. Using a 7-day window, average annual bleeds (total bleeds + patient-months)¹² among patients with ≥ 1 bleed equaled 2.31 (range: 1-33) for hemophilia A and 1.92 (range: 1-18) for hemophilia B. Results were similar for a 10-day window (hemophilia A: 2.21 (1-31), hemophilia B: 1.81 (1-14)) and 14-day window (hemophilia A: 2.10 (1-24), hemophilia B: 1.69 (1-12)). A 1-day window produced somewhat higher numbers (hemophilia A: 2.99 (1-66), hemophilia B: 2.72 (1-45)), but pairwise rank correlation remained high across the four assumptions (coefficients ≥ 0.99 , p-values <0.01 for both disease types). Frequencies are comparable to a large US-based study reporting bleeds in moderately-severe patients, albeit smaller than studies of severe patients. **CONCLUSIONS:** Claims data can be utilized to construct stable, robust indices of bleeding events in hemophilia patients, permitting reliable studies of factors influencing bleeding frequency and healthcare burden.

DB3

THE IMPLICATIONS OF USING A 30-, 60-, OR 90-DAY GAP IN TREATMENT TO SPECIFY LINES OF CARE IN GASTRIC CANCER TREATMENT

Seal B¹, Shermock KM², Asche CV³, Kreilick C¹, Xia F¹, Kish J⁴, Zagadailov EA⁴, Eaddy M⁴¹Bayer Healthcare Pharmaceuticals, Whippany, NJ, USA, ²The Johns Hopkins Medical Institutions, Baltimore, MD, USA, ³University of Illinois College of Medicine at Peoria, Peoria, IL, USA, ⁴Xcenda, Palm Harbor, FL, USA

OBJECTIVES: Compare changes in patterns of care and duration of therapy resulting from increasing the treatment gap designating a new line of therapy in metastatic (M) gastric cancer (GaCa). **METHODS:** Two large integrated claims databases (Pharmetrics, MarketScan) spanning July 2008 to September 2012 were used to identify patients ≥ 18 years old diagnosed and treated for GaCa. Patients were required to be continuously enrolled for ≥ 6 months pre- and post-diagnosis. Eligible patients were stratified into cohorts based on the presence and timing of metastasis (M) diagnosis: no metastasis (NM), ≤ 120 days (M1), and ≥ 121 days (M2). Treatment gap intervals were varied at ≥ 30 , ≥ 60 and ≥ 90 days to indicate the start of a new line of chemotherapy. **RESULTS:** There were 6,509 (3,486 NM; 1,469 M1; 654 M2) and 3,203 (2,004 NM; 875 M1; 324 M2) patients in each of the databases meeting all inclusion criteria. Comparing the 30- and 90-day gaps, mean length of treatment (days) increased for M1 patients from 69.8-71.0 to 83.4-84.5 in first, 55.4-56.6 to 55.7-60.3 in second, and 56.5-59.7 to 60.1-64.9 in third line. Using a 30-day gap, 46.4%-54.2% of

M1 and 36.1%-46.6% of M2 received second line while 25.6%-32.3% of M1 and 18.2%-25.1% of M2 received third line. Increasing the gap to 60 days decreased the total rate of second line therapy slightly for M1 patients to 43.0%-51.3% and to 33.0%-45.1% for M2. The rate of third-line therapy was similarly lower at 23.0%-30.0% for M1 patients and 17.3%-23.2% for M2. Increasing from a 60-day to 90-day gap resulted in an absolute decline in the 60-day rate of therapy of 0.8%-2.6% in second line and 0.3%-3.1% in third line across both the M1/M2 groups. **CONCLUSIONS:** The data are in agreement between the 2 databases, and analysis by varying treatment gaps did not significantly impact results.

DB4

DEVELOPMENT AND VALIDATION OF ALGORITHMS TO IDENTIFY STATIN INTOLERANCE IN A US ADMINISTRATIVE DATABASE

Foody JM¹, Lamerato L², Dalal M³, Sung JC³, Khan I³, Jhaveri M³, Koren A³, Schulman KL⁴¹Harvard Medical School, Boston, MA, USA, ²Henry Ford Health System, Detroit, MI, USA, ³Sanofi US, Inc., Bridgewater, NJ, USA, ⁴Outcomes Research Solutions, Inc., Bolton, MA, USA

OBJECTIVES: Develop and validate an algorithm to define statin intolerance (SI) in an administrative database (AD). **METHODS:** Adults with ≥ 1 qualifying change in statin therapy and ≥ 1 prior diagnosis of hyperlipidemia, hypercholesterolemia, or mixed dyslipidemia were identified from the AD of the Health Alliance Plan at Henry Ford Health System (HFHS). A sample of 1000 patients was drawn from the pool of eligible adults using an 80/20 ratio of patients taking a moderate- to low-intensity statin or a high-intensity statin at the time of qualifying change in therapy. Statin utilization and adverse events data were abstracted from the AD and the HFHS electronic medical record (EMR). Patients were stratified by high or low cardiovascular risk based on comorbidities, and any SI was categorized as absolute (AI) or titration (TI). In both the AD and the EMR, identification of SI was based on statin treatment patterns and potential statin-related adverse events. With EMR as the reference, measures of concordance (Cohen's kappa κ) and accuracy (sensitivity, specificity, positive predictive value [PPV]) were reported for AD algorithms. **RESULTS:** In the sample population ($n=990$), any SI was identified in 11.5% and 14.0%, AI in 2.2% and 3.1%, and TI in 9.7% and 11.8% of patients in the EMR and the AD, respectively. The algorithm identifying any SI had substantial concordance ($\kappa=0.66$) and good sensitivity (78.1%), but modest PPV (64.0%). The TI algorithm performed better ($\kappa=0.74$, sensitivity=85.4%, PPV=70.1%) than the AI algorithm ($\kappa=0.40$, sensitivity=50.0%, PPV=35.5%). Specificity was high (>94%) across all 3 algorithms. In the high cardiovascular risk cohort ($n=353$), the any SI algorithm demonstrated robust concordance ($\kappa=0.73$) and good sensitivity (80.9%) and PPV (75.3%), all of which were even higher for TI. **CONCLUSIONS:** A conservative but comprehensive, easily implementable, and valid SI algorithm from an AD is available for real-world research.

HEALTH CARE MANAGEMENT STUDIES

HM1

UTILIZATION OF ANTIDIABETICS AFTER FDA SAFETY ANNOUNCEMENTS

Ding Y¹, Gascue L¹, Lu Y², Ning N¹, Joyce C¹¹University of Southern California, Los Angeles, CA, USA, ²Harbor-UCLA Medical Center, Torrance, CA, USA

OBJECTIVES: FDA-issued safety alerts and warnings play a vital role in post-market drug surveillance. We examine the effects of the FDA safety announcements for rosiglitazone and pioglitazone on the utilization of these drugs and other oral antidiabetics. **METHODS:** We link safety announcements from the FDA MedWatch database to Medicare drug claims (Parts D & B) from 2006 to 2010. We examine the timing, direction and level of demand responses to safety announcements, and how they differ by patients' race/ethnicity, socioeconomic status and plan type (PDP vs MA-PD). We then estimate the fraction of patients that continue using an "alerted" medication, switch to another oral antidiabetic, or stop use altogether (without adding another oral medication), and how these responses differ by patient group and plan type. **RESULTS:** The demand for rosiglitazone plummeted after the second safety alert (in May 2007), and decreased further after a (black box) warning was issued (in August). After the alert, 27% to 28% of rosiglitazone users switched to another oral antidiabetic (predominantly pioglitazone) within 6 months of the alert depending on patient groups and plan type; 28% to 33% discontinued use of rosiglitazone, but did not add another oral antidiabetic; 38% to 44% continued using rosiglitazone. After the warning, the numbers were 17% to 19%, 30% to 32% and 49% to 52% respectively. Discontinuation rates were slightly higher among Hispanics (32%) and those in MA-PD plans (32%). In contrast, the demand response for pioglitazone was more muted, while it increased slightly after the warning (in August). **CONCLUSIONS:** The demand response to safety warnings for rosiglitazone was large and abrupt, and a substantial fraction of those who stopped did not replace it with another oral antidiabetic. The demand response was fairly constant across race/ethnicity, socioeconomic status, and plan type, although large responses raise concern about adverse health consequences.

HM2

DIFFERENCES IN MASTECTOMY RATES BASED ON HORMONE RECEPTOR STATUS IN EARLY STAGE TUMORS: A SEER DATABASE ANALYSIS

Hinyard L, Schwartz T

Saint Louis University, St. Louis, MO, USA

OBJECTIVES: Breast cancer molecular subtypes provide important prognostic information that is useful for determining adjuvant treatment strategies; however, there is no evidence to indicate molecular subtypes should influence choice of surgical treatment. The purpose of this study is to investigate the rates of mastectomy (TM) versus lumpectomy (BCT) for each T-stage subgroup based on hormone receptor status. **METHODS:** The SEER registry was queried for all females ages 15-85 diagnosed with stage T1 or T2 invasive breast cancer from 2010-2011. Patients were stratified by T-stage and race. Logistic regression was used within each stratum to compare